Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 14/20 | 0.52 |
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | JAK3 | P52333 | 4/20 | 0.52 |
| ▸ | ULK1 | O75385 | 2/20 | 0.52 |
| ▸ | CDC7 | O00311 | 2/20 | 0.52 |
| ▸ | PLK4 | O00444 | 2/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.52 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.52 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | PAK4 | O96013 | 2/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | PRKCG | P05129 | 2/20 | 0.52 |
| ▸ | INSR | P06213 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608189 | 0.96 | JAK2 (0.49) | PTK2JAK2JAK3ULK1CDC7 | |
| SCHEMBL1606952 | 0.94 | INSR (0.53) | PTK2JAK2JAK3ULK1CDC7 | |
| SCHEMBL1605710 | 0.93 | JAK3 (0.43) | PTK2JAK2JAK3ULK1CDC7 | |
| SCHEMBL1606991 | 0.90 | ALK (0.47) | PTK2JAK2JAK3ULK1CDC7 | |
| SCHEMBL1607094 | 0.90 | ALK (0.65) | PTK2JAK2JAK3ULK1CDC7 | |
| SCHEMBL1606253 | 0.89 | ALK (0.59) | PTK2JAK2JAK3ULK1CDC7 | |
| SCHEMBL1605651 | 0.89 | ALK (0.46) | PTK2JAK2JAK3ULK1CDC7 | |
| SCHEMBL1607194 | 0.89 | PTK2 (0.51) | PTK2JAK2JAK3ULK1CDC7 | |
| SCHEMBL1606289 | 0.87 | PKMYT1 (0.42) | PTK2JAK2JAK3ULK1CDC7 | |
| SCHEMBL1606385 | 0.87 | ALK (0.61) | PTK2JAK2JAK3ULK1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304422-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | claimed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | claimed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | claimed |
| WO-2008118822-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-8304422-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008118822-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PTK2 468/4885JAK2 2/4885JAK3 1/4885 |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | PTK2 314/4885JAK2 3/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.